5 Oversold Biotech Stocks To Buy Right Now

In this article, we will be taking a look at 5 oversold biotech stocks to buy right now. To read our detailed analysis of the biotech sector, you can go directly to see the 11 Oversold Biotech Stocks To Buy Right Now.

5. Ovid Therapeutics Inc. (NASDAQ:OVID)

Number of Hedge Fund Holders: 9

14-day RSI Value: 24.4

Ovid Therapeutics Inc. (NASDAQ:OVID) is a biopharmaceutical company that develops impactful medicines for patients with epilepsies and seizure-related disorders. It is based in New York.

Nine hedge funds were long Ovid Therapeutics Inc. (NASDAQ:OVID) in the fourth quarter, with a total stake value of $59.7 million.

4. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Number of Hedge Fund Holders: 33

14-day RSI Value: 23.6

An Overweight rating and $30 price target were maintained on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on March 13 by Jeffrey Hung at Morgan Stanley.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biotech company that develops and commercializes medicines addressing central nervous system disorders. It is based in San Diego, California.

There were 33 hedge funds long ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the fourth quarter, with a total stake value of $1.9 billion.

3. Spruce Biosciences, Inc. (NASDAQ:SPRB)

Number of Hedge Fund Holders: 10

14-day RSI Value: 21.7

Spruce Biosciences, Inc. (NASDAQ:SPRB) had 10 hedge funds long its stock in the fourth quarter, with a total stake value of $26.1 million.

Based in South San Francisco, California, Spruce Biosciences, Inc. (NASDAQ:SPRB) develops novel therapies for rare endocrine disorders.

On March 14, JMP Securities’ analyst Jonathan Wolleben maintained a Market Outperform rating and $3 price target on Spruce Biosciences, Inc. (NASDAQ:SPRB).

2. Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX)

Number of Hedge Fund Holders: 36

14-day RSI Value: 20.5

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is based in Cambridge, Massachusetts. It is a commercial-stage biotech company that develops treatments for amyotrophic lateral sclerosis and neurodegenerative diseases.

We saw 36 hedge funds long Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) in the fourth quarter, with a total stake value of $329.7 million.

A Buy rating and an $8 price target were maintained on Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) on March 12 by Andrew Fein at HC Wainwright & Co.

1. AN2 Therapeutics Inc. (NASDAQ:ANTX)

Number of Hedge Fund Holders: 17

14-day RSI Value: 17.4

A Market Perform rating and $7 price target were maintained on AN2 Therapeutics Inc. (NASDAQ:ANTX) on February 13 by Joseph Schwartz at Leerink Partners.

There were 17 hedge funds long AN2 Therapeutics Inc. (NASDAQ:ANTX) in the fourth quarter, with a total stake value of $252.1 million.

AN2 Therapeutics Inc. (NASDAQ:ANTX) is a clinical-stage biotech company that develops treatments for rare, chronic, and serious infectious diseases. It is based in Menlo Park, California.

See also 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds and 10 Biotech Stocks with Huge Potential.